

Endocrine Abstracts

September 2020 Volume 70
ISSN 1479-6848 (online)

22nd European Congress of
Endocrinology

5-9 September 2020, European Society of Endocrinology

eECE 2020
22nd European Congress of Endocrinology



published by
bioscientifica

Online version available at
www.endocrine-abstracts.org



22nd European Congress of Endocrinology 5-9 September 2020, European Society of Endocrinology

EDITORS

Abstracts were marked by the Abstract Marking Panel and selected by the Programme Organising Committee

e-ECE 2020 Mini-Programme Organising Committee

Andrea Giustina (Italy), **ESE President**
Martin Reincke (Germany), **ESE President-Elect**
Bulent Yildiz (Turkey), **ESE Treasurer (until May 2020)**
Riccarda Granata (Italy), **ESE Congress Committee Chair**

Attila Balázs Patócs (Hungary), **2020 POC Co-Chair**
Jens Otto Lunde Jørgensen (Denmark), **2020 POC Co-Chair**
Daniela Cota (France), **2021 POC Co-Chair**
Lars Rejnmark (Denmark), **2021 POC Co-Chair**

Ljiljana Marina (Serbia), **EYES Chair**
Manel Puig Domingo (Spain), **2020 POC Member**
Mónica Marazuela (Spain), **ESE Secretary**

Programme Organising Committee

Riccarda Granata (Italy), **ESE Congress Committee Chair**
Jens Otto Lunde Jørgensen (Denmark), **Clinical Co-Chair**
Attila Balázs Patócs (Hungary), **Basic Science Co-Chair**
Michal Kršek (Czech Republic), **Local Organising Committee Chair**
Zhanna Belaya (Russian Federation)
Nienke Biermasz (The Netherlands)
Jens Bollerslev (Norway)

Daniela Cota (France)
Ashley Grossman (UK)
Csilla Krausz (Italy)
Madalina Musat (Romania)
Uberto Pagotto (Italy)
Agnieszka Piekliko-Witkowska (Poland)
Vincent Prevot (France)
Manel Puig-Domingo (Spain)

Lars Rejnmark (Denmark)
Mark Sherlock (Ireland)
Marilyn Theodoropoulou (Germany)
Pierre Val (France)
AJ van der Lely (The Netherlands)
Wim van Hul (Belgium)
Greisa Vila (Austria)
Maria Chiara Zatelli (Italy)

Ex Officio Members

Andrea Giustina (Italy), **ESE President**
Martin Reincke (Germany), **ESE President-Elect**
Bulent Yildiz (Turkey), **ESE Treasurer (until May 2020)**
Wiebke Artl (UK), **Editor in Chief, European Journal of Endocrinology**

Josef Köhrle (Germany), **Editor in Chief, Endocrine Connections**
Felix Beuschlein (Switzerland), **ESE Clinical Committee Chair**
Robin Peeters (Switzerland), **ESE Science Committee Chair**
Riccarda Granata (Italy), **ESE Congress Committee Chair**

Marek Ruchala (Poland), **ECAS Representative**
Mehul Dattani (UK) (Switzerland), **ESPE Representative**
Luis Cardoso (Portugal), **EYES Representative**

Abstract Marking Panel

Marker Name	Country	L Czupryniak Poland	D Grigorie Romania	M Krsek Czech Republic	N Papanas Greece	E Shestakova Russia
M Alevizaki Greece		J Dahlgren Sweden	P Groop Finland	A Kurylowicz Poland	A Patócs Hungary	M Shestakova Russia
K Amrein Austria		P Dahlgvist Sweden	A Grossman UK	E Lalli France	R Peeters The Netherlands	M Simoni Italy
C Andoniadou UK		C Daousi UK	L Groussin France	B Langdahl Denmark	S Pekic Serbia	J Skrha Austria
G Assié France		M Dattani UK	G Gruden Italy	B Lapauw Belgium	N Pellegata Germany	P Soares Portugal
S Babajko France		C Dayan UK	L Guasti UK	J Laven The Netherlands	L Perez-Rivas Germany	A Solini Italy
C Badiu Romania		J de Castro Portugal	M Haluzik Czech Republic	G Lavery UK	H Perrild Denmark	A Spada Italy
A Baranowska-Bik Poland		W de Herder The Netherlands	R Hampl Czech Republic	L Laviola Italy	L Persani Italy	J Spranger Germany
A Barlier France		E de Koning The Netherlands	V Hána Czech Republic	L Lazurova Slovakia	G Perseghin Italy	A Spyrglou Germany
K Basham USA		W Dhillon UK	F Hannan UK	H Lefebvre France	M Petakov Serbia	G Stalla Germany
A Beckers Belgium		G Di Dalmazi Germany	A Heck Norway	J Leger France	A Piekliko-Witkowska Poland	E Stener-Victorin Sweden
P Beck-Peccoz Italy		E Diamanti-Kandarakis Greece	M Heikinheimo Finland	T Links The Netherlands	V Pirags Latvia	C Strasburger Germany
Z Belaya Russia		C Dieguez Spain	A Hoellich Germany	P Lips The Netherlands	C Poiana Romania	C Stratakis USA
J Bertherat France		E Dirinck Belgium	L Holland The Netherlands	S Llahana UK	R Poladian Lebanon	A Tabarin France
M Bidlingmaier Germany		M Donath Switzerland	A Hubalewska-Dydejczyk Poland	A Luger Austria	S Polyzos Greece	T Tankova Bulgaria
N Biermasz The Netherlands		J Drouin Canada	I Huhtaniemi UK	S Lund Denmark	P Poplawski Poland	M Tena-Sempere Spain
W Bik Poland		L Duntas Greece	E Husebye Norway	R Luque Spain	V Popović Serbia	N Tentolouris Greece
K Birkeland Norway		A Dwyer USA	P Igaz Hungary	D Macut Serbia	M Porta Italy	M Terzolo Italy
K Boelaert UK		G Eisenhofer Germany	I Ilvovskaya Russia	D Maiter France	M Poutanen Finland	M Theodoropoulou Germany
J Boguslawska Poland		V Elian Romania	E Isenovic Serbia	E Mamedova Russia	D Power Portugal	C Thompson Ireland
J Bollerslev Norway		F Fallo Italy	M Jaffrain-Rea Italy	M Mannelli Italy	M Puig Domingo Spain	H Timmers The Netherlands
R Bouillon Belgium		M Fassnacht Germany	B Jarzab Poland	E Mannucci Italy	C Quarta France	M Toth Hungary
M Brandi Italy		J Favier France	K Jazdzewski Poland	F Mantero Italy	S Radian Romania	P Touraine France
D Branisteanu Romania		R Feelders The Netherlands	N Jessen Denmark	G Mantovani ITALY	O Ragnarsson Sweden	R Trifanescu Romania
K Briot France		U Feldt-Rasmussen Denmark	D Jezova Slovakia	M Marazuela Spain	N Rahman Finland	A Tsapas Greece
T Brue France		F Fernandes Rosa France	G Johansson Sweden	L Marina Serbia	E Rajpert-De Meyts Denmark	E Tsourdi Germany
G Brunetti Italy		S Fica Romania	A Jørgensen Norway	N Matikainen Finland	M Rauner Germany	MTzanela Greece
C Buchanan UK		E Fliers The Netherlands	J Jørgensen Denmark	C McCabe UK	G Raverot France	E Valassi Spain
P Burman Sweden		S Franks UK	U Kaiser USA	O Meijer The Netherlands	M Reincke Germany	G Valk The Netherlands
H Butz Hungary		W Fraser UK	G Kallias Greece	L Metherell UK	L Rejnmark Denmark	E van den Akker The Netherlands
S Cannavo Italy		J Frystyk Denmark	C Kanaka-Gantenbein Greece	D Miljic Serbia	S Rice UK	erlands
J Cap Czech Republic		L Fugazzola Italy	G Kanakis Greece	J Mittag Germany	M Robledo Spain	A van der Lely The Netherlands
C Capatina Romania		C Fuà Germany	T Kararup Hansen Denmark	N Moller Denmark	P Rodien France	J van Eck The Netherlands
M Caprio Italy		F Gabalec Czech Republic	D Karasek Czech Republic	L Morin-Papunen Finland	H Romijn The Netherlands	W van Hul Belgium
P Caron France		S Gaberšček Slovenia	N Karavitaki UK	A Mukherjee UK	C Ronchi Italy	M Vantyghem France
J Castaño Spain		M Gabete Spain	A Karlsson Sweden	M Musat Romania	R Ross UK	G Vila Austria
H Cederberg-Famminen Finland		R Gärtner Germany	S Kaser Austria	E Nagy Hungary	R Roussel France	E Visser The Netherlands
O Chabre France		B Gatta Cherifi France	D Kastelan Croatia	S Neggers The Netherlands	N Rucci Italy	J Visser The Netherlands
P Chanson France		L Gennari Italy	J Kaufman Belgium	J Newell-Price UK	M Ruchala Poland	V Volke Estonia
K Chatterjee UK		M Gheorghiu Romania	M Keil USA	N Nicolaidis Greece	E Rutten Belgium	J Widimsky Czech Republic
N Cherradi France		I Gherlan Romania	F Kelestimur Turkey	D Niculescu Romania	S Sanack Turkey	W Wiersinga The Netherlands
M Chiara Zatelli Italy		P Giacobini France	R Kineman USA	M Niedziela Poland	D Santi Greece	I Wilkinson UK
F Chiarelli Italy		J Giordano Italy	T Kocjan Slovenia	R Nogueiras Spain	P Saunders UK	P Williams Germany
J Chowen Spain		A Giustina Italy	J Kopchick USA	B Obermayer-Pietsch Austria	C Schalin-Jäänti Finland	S Wudy Germany
S Christin-Maitre France		M Godlewska Poland	M Korbonits UK	C Olareus Norway	S Schmid Germany	P Yeoh UK
M Cohen-Solal France		J Gomez-Ambrosi Spain	B Kos-Kudla Poland	P Oliveira Portugal	J Schopohl Germany	B Yildiz Turkey
D Cota France		D Goulis Greece	C Krausz Italy	D Olsson Sweden	D Schulte Germany	M Zarkovic Serbia
D Cuthbertson UK		R Granata Italy	M Kroiss Germany	K Øystese Norway	P Schwarz Denmark	M Zennaro France
		C Gravholt Denmark	N Krone UK	U Pagotto Italy	M Sherlock Ireland	

The European Society of Endocrinology would like to thank its Corporate Members and the sponsors of e-ECE 2020.

Premium Corporate Members

Akcea Therapeutics
Ipsen
Pfizer
Recordati Rare Diseases Sarl
Takeda

Corporate Members

Advanced Accelerator Applications
Amryt Pharmaceuticals (formerly Aegerion)
Diurnal
HRA Pharma
Kyowa Kirin International
Merck Serono
Novo Nordisk
Sandoz International GmbH
Siemens-Healthineers
Strongbridge Biopharma
Uni-Pharma

Supporters

Chiasma
Crinetics Pharmaceuticals
Isotopen Technologien Munchen AG

Gold Sponsors

Ipsen
Pfizer
Takeda

Silver Sponsor

Recordati Rare Diseases

Bronze Sponsors

Advanced Accelerator Applications
Amryt Pharma
HRA Pharma Rare Diseases
Kyowa Kirin
Novo Nordisk



European Society of Endocrinology
Starling House, 1600 Parkway
North, Bristol, BS34 8YU, UK

Tel: +44 (0) 1454 642247
Fax: +44 (0) 1454 642222
E-mail: info@euro-endo.org
Website: <http://www.endocrinology.org>



Congress Secretariat:

Bioscientifica Ltd
Starling House, 1600 Parkway
North, Bristol, BS34 8YU, UK

Tel: +44 (0)1454 642240
Fax: +44 (0)1454 642222
E-mail: ece2020@endocrinology.org
Website: www.ece2020.org

CONTENTS

e-ECE 2020

22nd European Congress of Endocrinology

PRIZE LECTURES AND BIOGRAPHICAL NOTES

The Geoffrey Harris Prize Lecture	AP1
The <i>European Journal of Endocrinology</i> Prize Lecture	AP2
European Hormone Medal Lecture	AP3
Clinical Endocrinology Trust Lecture	AP4

PLENARY LECTURES

Exercise as medicine – a translational perspective	PL1
Glucocorticoids in cancer: a new paradigm	PL2
Harnessing the microbiome in metabolic disease	PL3
Mechanisms for SARS-CoV-2 cell entry	PL4
Maternal thyroid hormone and child brain development	PL5
It takes thyroid hormone to make sense	PL6
Effects of EDCs on neuro-endocrine systems and behaviour	PL7

SYMPOSIA

New horizons in pheochromocytoma and paraganglioma	S1.1–S1.3
Osteoporosis and fracture prediction	S2.1–S2.3
Controversial issues in bariatric surgery	S3.1–S3.3
Unveiling signatures in pituitary neuroendocrine tumours	S4.1–S4.3
Hyperthyroidism across the lifespan	S5.1–S5.3
Adrenocortical carcinoma	S6.1–S6.3
Endocrine disruptors, just a hype or not?	S7.1–S7.3
PCOS: from Genetics to Treatment	S8.1–S8.3

COVID-19 SESSION

Endocrine targets related to COVID infection	CS1.1
Managing the Cytokine storm.	CS1.2
How strong is obesity as a risk factor for COVID-19 patients	CS1.3

ORAL COMMUNICATIONS

Adrenal and Cardiovascular Endocrinology	OC1.1–OC1.7
Bone and Calcium	OC2.1–OC2.7
Diabetes, Obesity, Metabolism and Nutrition	OC3.1–OC3.7
Pituitary and Neuroendocrinology	OC4.1–OC4.7
Thyroid	OC5.1–OC5.7
Hot Topics (including COVID -19)	OC6.1–OC6.7
Endocrine-related Cancer	OC7.1–OC7.7
Environmental Endocrinology	OC8.1–OC8.6
Reproductive and Developmental Endocrinology	OC9.1–OC9.7
Young Investigators	YI1–YI12

AUDIO EPOSTER PRESENTATIONS

Adrenal and Cardiovascular Endocrinology	AEP1–AEP121
Bone and Calcium	AEP122–AEP242
Diabetes, Obesity, Metabolism and Nutrition	AEP243–AEP527
Endocrine-related Cancer	AEP528–AEP540, AEP655
Environmental Endocrinology	AEP541–AEP542
General Endocrinology	AEP543–AEP559
Pituitary and Neuroendocrinology	AEP560–AEP777
Reproductive and Developmental Endocrinology	AEP778–AEP856
Thyroid	AEP857–AEP1000
Hot topics (including COVID-19)	AEP1001–AEP1110

EPOSTER PRESENTATIONS

Adrenal and Cardiovascular Endocrinology	EP1–EP58
Bone and Calcium	EP59–EP123
Diabetes, Obesity, Metabolism and Nutrition	EP124–EP265
Endocrine-related Cancer	EP266–EP270
Environmental Endocrinology	EP271
General Endocrinology	EP272–EP279
Pituitary and Neuroendocrinology	EP280–EP373
Reproductive and Developmental Endocrinology	EP374–EP410
Thyroid	EP411–EP532
Hot topics (including COVID-19)	EP533–EP589

AUTHOR INDEX

AEP776

To optimize the acute octreotide suppression test in predicting the efficacy of long acting somatostatin analogues in acromegaly

Gao Yuting, Zhihong Liao, Qin Du & Ke Cai

The First Affiliated Hospital of Sun Yat-sen University, Department of Endocrinology and Metabolism, Guangzhou, China

A 6-hour octreotide suppression test (OST) is useful in the selection of patients with acromegaly for chronic somatostatin depot analogues treatment. However, it is time consuming and that brings inconvenience to patients. We aim to simplify the blood sampling of OST, and determine the reliability of a short version of the classic 6-hour OST. The data provided in the supplementary tables of the primary manuscript were used to re-analyze the efficacies of the simplified OST tests. SPSS Software Version 25 was used for data analyses. To find the best receiver operating characteristic (ROC) curve, several analysis of the shorten-test (including 2-hour, 3-hour, 4-hour and, 6-hour's tests) were performed, and compared the parameters of ROC with that of 2-day's examination to find a proper shorten test period. After calculating, \square GH (0–3 h) more than 80.51% and 91.84% provided the best predictors of a good GH response (sensitivity 96.9%, specificity 85.7%) and a good IGF-1 response (sensitivity 86.7%, specificity 81.3%). \square AUC (0–3 h) more than 71.07% provided the best predictor of a good tumor size response (sensitivity 81.8%, specificity 90.6%). From these results, we conclude that OST could be simplified as the 3-hour measurements. The \square GH (0–3 h) is the best optimistic parameter to predict a good GH, or IGF-1, response, while the \square AUC (0–3 h) is the best for a good tumor size response to short-term efficacy of SSA in acromegaly.

Keywords: acromegaly, somatostatin analogues, remission prediction, octreotide suppression test.

DOI: 10.1530/endoabs.70.AEP776

AEP777

Acromegaly is associated with reduced socioeconomic status and more so in female patients: A nationwide population-based studyJakob Dal^{1,2}, Eigil H Nielsen¹, Ulla Feldt-Rasmussen³, Marianne Andersen⁴, Claus Feltoft⁵, Peter Vestergaard^{1,2}, Kirstine Stochholm⁶ & Jens Otto Jørgensen⁶

¹Aalborg University Hospital, Endocrinology, Aalborg, Denmark; ²Steno Diabetic Center Northjælland, Aalborg, Denmark; ³Copenhagen University Hospital, Department of Endocrinology and Metabolism, Rigshospitalet, Copenhagen, Denmark; ⁴Odense University Hospital, Endocrinology, Denmark; ⁵Herlev Hospital, Endocrinology, Denmark; ⁶Aarhus University Hospital, Department of Endocrinology and Internal Medicine, Denmark

Context

Acromegaly is a rare and insidious disease associated with severe somatic morbidity but data on socioeconomic status are scarce.

Objective

To study the socioeconomic status in acromegaly in a population based, nationwide follow-up study.

Patients and methods

All incident cases of acromegaly ($n=576$) during the period 1997–2010 were included, representing 10.116 years at risk. For every patient, 100 persons were sampled from the general population matched on date of birth and gender (comparison cohort). Cox regression and hazard ratios (HR) or conditional logistic regression with 95% confidence intervals (CI) were used.

Main outcome measures

Annual income, allocation of cash benefits, retirement, cohabitation, separation, parenthood and education level.

Results

The proportion of retirement was significantly increased in patients with acromegaly after the time of diagnosis (HR 1.43, CI95% 1.26–1.62) and also during the 5-year pre-diagnostic period (HR : 1.15, CI95% 1.03–1.28). The utilisation of cash benefits was increased in patients with acromegaly in the period preceding the time of diagnosis. Among patients who maintain a paid job, the annual income was similar to the reference population. Compared with the background population, cohabitation was less prevalent (HR : 0.69, CI : 0.50–0.95) as was parenthood (HR : 0.56, CI : 0.39–0.80), whereas neither educational level (HR: 0.61, CI : 0.35–1.06) nor the prevalence of separation (HR : 1.13, CI : 0.86–1.47) were different in acromegaly. A reduced socioeconomic status was present before the diagnosis of acromegaly. Female gender was associated with a significantly worse socioeconomic status (Table 1).

Table 1 Hazard ratios of the various outcomes.

After diagnosis	Female	P-value	Male	P-value
Mortality	1.56 (1.27–1.91)	< 0.01	1.32 (1.09–1.61)	< 0.01
Retirement	1.58 (1.33–1.87)	< 0.01	1.30 (1.08–1.55)	< 0.01
Education	0.65 (0.34–1.25)	0.19	0.52 (0.17–1.63)	0.26
Separation	1.28 (0.89–1.83)	0.18	0.99 (0.67–1.47)	0.95
Cohabitation	0.62 (0.38–1.00)	0.05	0.76 (0.50–1.16)	0.20
Parenthood	0.33 (0.17–0.67)	< 0.01	0.74 (0.48–1.12)	0.16
5-years pre-diagnosis				
Retirement	1.14 (0.98–1.33)	0.08	1.16 (0.99–1.36)	0.07
Cohabitation	0.75 (0.53–1.06)	0.10	1.06 (0.79–1.41)	0.71
Parenthood	0.55 (0.34–0.87)	0.01	0.82 (0.60–1.13)	0.23

Conclusion

1. Socioeconomic status is impaired in patients with acromegaly even before diagnosis. 2. Females and patients without disease remission have significantly worse outcomes. 3. Early diagnosis and effective treatment are essential not least in female patients.

DOI: 10.1530/endoabs.70.777

Reproductive and Developmental Endocrinology

AEP778

Case-control study on ACE2 expression in children with short statureGianluca Tornese¹, Federica Tonon², Francesca Nicolardi², Barbara Toffoli¹, Maria Chiara Pellegrin¹, Egidio Barbi¹, Bruno Fabris² & Stella Bernardi²

¹Hospital Burlo Garofolo, Trieste, Italy; ²University of Trieste, Department of Medical Sciences, Trieste, Italy

Background

Short stature is one of the most common presentations to paediatric endocrinologists. It is estimated that despite all the exams, in 50–90% of cases, children are labelled as having idiopathic short stature. It has been recently reported that genetic ACE2 deficiency is associated with reduced body weight as well as with impaired gestational weight gain and fetal growth restriction in pregnancy. It has been argued that ACE2 deficiency, which is usually associated with an increase of tissue Angiotensin II, could be associated with prenatal as well as postnatal changes leading to reduced growth (such as uterine artery dysfunction and IGF-1 reduction, respectively). Based on these premises, the aim of our study was to evaluate whether there was a difference of ACE2 expression in children with short stature as compared to age-matched controls.

Methods

We designed an exploratory case-control study aiming at recruiting consecutively 40 children with short stature (cases) and 40 controls presenting at the Endocrinology Service, aged 2–13 years, excluding those with acute intercurrent diseases, diabetes, renal insufficiency, syndromes and/or on medications. After signing the informed consent to participating in the study, children underwent a medical visit and a fasting blood sampling. Peripheral blood mononuclear cells (PBMC) were isolated to extract mRNA for gene expression analyses. Sera were collected for protein measurements.

Results

Children with short stature ($n=17$) presented with lower height and body weight as compared to controls ($n=18$). Our preliminary data show that children with short stature exhibited a significant reduction of ACE2 gene expression, and a significant increase of ACE/ACE2 ratio in PBMC. This was associated with a modest increase of Angiotensin II/Angiotensin 1–7 ratio. Our multivariate analysis showed that across the groups ACE2 was independently associated with height but not with body weight.

Conclusions

To our knowledge, this is the first study investigating ACE2 expression in a paediatric population. Our preliminary results, showing that ACE2

expression is significantly reduced in children with short stature, are in line with the literature. This study could represent the basis for further investigations aiming at establishing the presence of a causal relationship between ACE2 deficiency and growth reduction, with further diagnostic and therapeutic perspectives

DOI: 10.1530/endoabs.70.AEP778

AEP779

Coagulation abnormalities in patients with Klinefelter syndrome compared to age-matched healthy controls: Cross-sectional assessment by thrombin generation test

Rita Indirli^{1,2}, Eriselda Profka², Walter Vena^{2,3}, Biagio Cangiano^{2,4}, Alessandro Pizzocaro³, Marco Bonomi^{2,4}, Marigrazia Clerici⁵, Erica Scalabrino⁵, Gherardo Mazziotti^{3,6}, Andrea Lania^{3,6}, Maura Arosio^{1,2}, Giovanna Mantovani^{1,2}, Armando Tripodi⁵ & Emanuele Ferrante¹
¹Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Endocrinology Unit, Milan, Italy; ²University of Milan, Department of Clinical Sciences and Community Health, Milan, Italy; ³Humanitas Clinical and Research Center, Endocrinology, Diabetology and Andrology Unit, Rozzano (MI), Italy; ⁴IRCCS Istituto Auxologico Italiano, Division of Endocrine and Metabolic Diseases and Lab. of Endocrine and Metabolic Research, Milan, Italy; ⁵Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico and Fondazione Luigi Villa, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy; ⁶Humanitas University of Milan, Department of Biomedical Sciences, Milan, Italy

Introduction

Klinefelter syndrome (KS) is known to be associated with an increased risk of venous thromboembolism and arterial thrombosis, but the aetiology behind this prothrombotic status has not been fully elucidated. The aim of this study was to cross-sectionally investigate the coagulative state in subjects with KS compared to age-matched healthy males.

Methods

Coagulation factors assessment, clinical characteristics collection and thrombin generation test (TGT) were performed in 58 consecutive KS patients and 58 controls. TGT is based on the continuous registration of thrombin generation (mediated by procoagulants) and decay (mediated by anticoagulants) using a fluorogenic substrate. The curve of thrombin concentrations (vertical axis) by time (horizontal axis) is called *thrombogram* and is described by the following parameters: *lag-time* (time from coagulation ignition to the formation of the first amounts of thrombin); *thrombin-peak* and *time-to-peak*; *endogenous thrombin potential (ETP)*, the area under the thrombin curve, measured with and without the addition of thrombomodulin; the *ETP-ratio* (ETP with/ETP without thrombomodulin), that may be considered the best parameter through which *in vivo* subtle procoagulant imbalance can be detected.

Results

No statistically significant difference was found between KS patients and healthy subjects in lag-time, thrombin-peak, time-to-peak or ETP; however, the ETP-ratio was significantly higher in KS compared to controls (0.73 and 0.66 respectively, $P < 0.001$). KS patients had higher circulating concentrations of Factor VIII ($P = 0.001$) and Fibrinogen ($P < 0.001$) and a higher Factor VIII/Protein C ratio ($P = 0.018$), while platelet count, PT ratio, aPTT ratio, Factor II, Protein C and Antithrombin were similar in the two groups. ETP-ratio was positively correlated with Factor VIII concentrations ($P = 0.007$, $\rho = 0.355$) and showed a trend of association with impaired fasting glucose ($P = 0.069$) and Factor VIII/Protein C ratio ($P = 0.072$, $\rho = 0.240$). Fibrinogen levels were positively associated with age ($P = 0.004$, $\rho = 0.401$), body mass index ($P = 0.001$, $\rho = 0.468$) and fasting plasma glucose ($P = 0.049$, $\rho = 0.356$), while FVIII did not show any correlation with metabolic parameters as well as age. Testosterone replacement therapy and smoke were not associated with any of the coagulation parameters.

Conclusion

As clinically suggested, a procoagulant imbalance is present in KS subjects and is possibly related to higher Factor VIII concentrations here demonstrated. While testosterone replacement therapy and smoking habit did not show a significant impact, other typical factors associated with thrombotic risk such as advanced age, BMI and altered glucose metabolism could further increase this imbalance by determining hyperfibrinogenemia.

DOI: 10.1530/endoabs.70.AEP779

AEP780

Radiiodine (RAI) as a new therapy for the treatment of ovarian cancer through the sodium/iodide symporter (NIS)

Lidia Mirela Mielu^{1,2}, Maria Paz Lopez-Molina¹, Patricia Mingo-Casas¹, Lucía Rodal-Bravo¹, Cristina Diego-Hernandez³, Pilar Pallarés¹, Custodia García-Jiménez⁴, Pilar Martín-Duque⁵ & Antonio De la Vieja^{1,2}
¹Instituto de Salud Carlos III, UFIEC, Majadahonda-Madrid, Spain; ²Instituto de Salud Carlos III, CiberOnc, Madrid, Spain; ³Hospital Universitario de Móstoles, Móstoles, Spain; ⁴Universidad Rey Juan Carlos, Móstoles, Spain; ⁵Instituto Aragonés de Ciencias de la Salud, Zaragoza, Spain

Introduction

Ovarian cancer is the most lethal gynecological malignancy. Early diagnosis has a survival rate of 90%. Unfortunately, more than 70% of cases are diagnosed when the cancer has already metastasized, and survival rates do not exceed 30% in these cases. The sodium iodide symporter (NIS) is an integral plasma membrane glycoprotein expressed in the basolateral surface of the thyroid gland, where it mediates active transport of iodide. Radiiodide therapy (RAI) through NIS is the most effective therapy in thyroid cancer. Our group has demonstrated that NIS is expressed in ovarian surface epithelium and is overexpressed in human epithelial ovarian cancer, establishing NIS as a tumor marker. The aim of this study is to determine whether endogenous expression of NIS in ovarian cancer can be used as therapeutic tool using-RAI in ovarian tumors.

Materials and methods

serous ovarian cancer cell line (SKOV3) was transfected permanently with exogenous NIS (SKOV3-hNIS) and *in vitro* characterized by different techniques (western-blot, PCR, flow cytometry, immunofluorescence, iodide uptake). *In vivo*, NIS-transfected and not transfected cells were injected into flanks of nude and NSGs mice. NIS tumor expression was analyzed by different techniques and NIS functionality in animal models was measured by SPECT-CT.¹³¹I treatment was tested in subcutaneous nude female mice. Human ovarian tumors samples received from the Mostoles Hospital were disaggregated and used to produce primary cultures and PDX animals.

Results

PCR and western-blot show NIS expression in both *in vitro* (cancer cells) and *in vivo* (xenotransplanted cells in animal models and human samples). Immunofluorescence and immunohistochemistry show that NIS expression occurs in plasma membrane. *In vitro* and *in vivo* (SPECT-CT) Iodide uptake assays show that the expression of NIS in plasma membrane is functional. ¹³¹I treatment in subcutaneous tumors show an overall decrease in tumor size of 71% vs a 632% increase in not treated tumors. We observed that more than 37% of tumors disappear in 25 days with just a single ¹³¹I dose.

Conclusion

NIS expression in human ovarian cancer cell lines is functional *in vitro* and *in vivo*, targeted to the plasma membrane, and able to accumulate iodide. A single dose of ¹³¹I reduces ovarian tumor growth in NIS-expressing tumors and is more effective than conventionally chemotherapy. Patient tumors are expressing NIS in the plasma membrane, which leads us to propose NIS as a therapeutic approach to the treatment of ovarian cancer through radio iodine.

DOI: 10.1530/endoabs.70.AEP780

AEP781

Luteinizing hormone/choriogonadotropin receptor (LHCGR) mediates different kinetics of G proteins, β -arrestins and cAMP activation

Elia Paradiso^{1,2}, Riccardo Benevelli¹, Clara Lazzaretti^{1,2}, Samantha Sperduti^{1,3}, Giulia Brigante^{1,4}, Manuela Simoni^{1,3,4,5} & Livio Casarini^{1,3}
¹University of Modena and Reggio Emilia, Unit of Endocrinology, Department of Biomedical, Metabolic and Neural Sciences, Modena, Italy; ²University of Modena and Reggio Emilia, International PhD School in Clinical and Experimental Medicine (CEM), Modena, Italy; ³University of Modena and Reggio Emilia, Center for Genomic Research, Modena, Italy; ⁴Azienda Ospedaliero-Universitaria di Modena. Baggiovara Hospital, Department of Medical Specialties, Modena, Italy; ⁵Institut National de la Recherche Agronomique, Unité Physiologie de la Reproduction et des Comportements, Nouzilly, France

Pituitary luteinizing hormone (LH) and placental human chorionadotropin (hCG) are two heterodimeric glycoprotein hormones regulating reproduction. They bind the same receptor (LHCGR) expressed in gonadal cells, activating hormone-specific G protein- and β -arrestins-dependent signaling cascades, before LHCGR internalization. LH induces preferential proliferative signals, while hCG activates mainly the steroidogenic pathway,